Article
MEX3A is a new diagnostic, independent prognostic biomarker and a promising therapeutic target in gliomas
2024-05-13
Abstract excerpt
<title>Abstract</title> <p>Gliomas are the most common malignant brain tumors with a dismal prognosis. Despite the progress in defining molecular features, no therapies targeting the known biomarkers significantly increase the survival rate of glioma patients. Recently, it has been demonstrated that high expression of Muscle Excess 3A (MEX3A) in gliomas correlates with poor overall survival (OS), yet its clinical...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 48b0fb9f-6111-5985-84e6-6c539e201822
- DOI
- 10.21203/rs.3.rs-4350316/v1
